FDA — authorised 29 November 2021
- Application: NDA214907
- Marketing authorisation holder: ON TARGET LABS
- Local brand name: CYTALUX
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Cytalux in United States
FDA authorised Cytalux on 29 November 2021
Marketing authorisations
FDA
- Status: approved
Other Oncology approved in United States
Frequently asked questions
Is Cytalux approved in United States?
Yes. FDA authorised it on 29 November 2021; FDA has authorised it.
Who is the marketing authorisation holder for Cytalux in United States?
ON TARGET LABS holds the US marketing authorisation.